Page last updated: 2024-09-03

gefitinib and metformin

gefitinib has been researched along with metformin in 25 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(metformin)
Trials
(metformin)
Recent Studies (post-2010) (metformin)
5,2315662,91917,7933,17612,526

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (8.00)29.6817
2010's19 (76.00)24.3611
2020's4 (16.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ1
Ekins, S; Williams, AJ; Xu, JJ1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Abraham, RT; Baker, A; Berggren, MI; Ihle, NT; Kirkpatrick, DL; Paine-Murrieta, G; Powis, G; Tate, WR; Wipf, P1
Dayekh, K; Dimitroulakos, J; Gorn-Hondermann, I; Ma, L; Niknejad, N1
Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D1
Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O1
Chen, CY; Chen, HJ; Chiu, HC; Huang, YC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Tseng, SC; Wo, TY1
Chen, H; Han, R; He, Y; Jiang, J; Li, K; Li, L; Lin, C; Liu, H; Sun, F; Wang, Y; Xiao, H; Yang, Z1
Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W1
Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K1
Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K1
Darko, KO; Huang, Y; Peng, CY; Peng, M; Su, Q; Tao, T; Tao, X; Xu, W; Yang, X1
Chen, HY; He, Y; Kang, J; Li, KL; Li, L; Wang, YB; Zhang, P1
Deng, J; Peng, J; Peng, M; Wang, Z; Xiao, D; Yang, X; Zhou, S1
Cai, Y; Han, S; Han, W; Hu, Q; Ran, J; Song, C; Tang, C; Wang, Y; Wei, Z; Xu, W; Yin, X; Zou, H1
Bai, J; Cai, S; Chen, H; Gao, C; Han, R; He, Y; Jiang, L; Li, L; Ren, B; Sun, J; Tian, K; Wang, H; Wang, Y; Wu, G; Xiao, HL; Xu, Z; Yang, Z; Zhang, XJ; Zhao, Y; Zhou, Q; Zhou, X1
Addison, C; Al-Kadi, E; Chambers, J; Dimitroulakos, J; Li, L; Li, X; McGarry, S; Mediratta, K; Phan, A; Sulaiman, A; Wang, L1
Chang, YL; Chen, YM; Chou, YC; He, CH; Hsu, CC; Huang, TY; Su, VY; Yang, KY; Yen, JC1
Li, G; Lin, Z; Mei, J; Xu, X1
Chen, BS; Lin, YC1

Reviews

2 review(s) available for gefitinib and metformin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Novel application of metformin combined with targeted drugs on anticancer treatment.
    Cancer science, 2019, Volume: 110, Issue:1

    Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Gefitinib; Humans; Metformin; Molecular Targeted Therapy; Treatment Outcome; Urinary Bladder Neoplasms

2019

Trials

2 trial(s) available for gefitinib and metformin

ArticleYear
A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.
    Clinical lung cancer, 2017, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Survival Analysis; Young Adult

2017
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23

    Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Mutation; Prognosis; Survival Rate

2019

Other Studies

21 other study(ies) available for gefitinib and metformin

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:9

    Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glucose Tolerance Test; Gonanes; Humans; Hyperglycemia; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Mice; Mice, SCID; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Quinazolines; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured

2005
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
    PloS one, 2012, Volume: 7, Issue:9

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Drug Synergism; Fibroblasts; Gefitinib; Gene Deletion; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lovastatin; Metformin; Mice; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction

2012
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jul-01, Volume: 19, Issue:13

    Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Metformin; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays

2013
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
    International journal of oncology, 2013, Volume: 43, Issue:6

    Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Hyaluronan Receptors; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Mice, SCID; Neoplasm Transplantation; Peptides; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays

2013
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase 3; MAP Kinase Kinase 6; Metformin; Mutation; MutS Homolog 2 Protein; p38 Mitogen-Activated Protein Kinases; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transgenes

2013
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, May-15, Volume: 20, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Interleukin-6; Kaplan-Meier Estimate; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2014
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
    Cancer letters, 2015, Dec-01, Volume: 369, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome

2015
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.
    Oncotarget, 2015, Dec-22, Volume: 6, Issue:41

    Topics: Animals; Antineoplastic Agents; Bleomycin; Blotting, Western; Epithelial-Mesenchymal Transition; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Diseases, Interstitial; Male; Metformin; Pulmonary Fibrosis; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta

2015
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
    International journal of oncology, 2016, Volume: 48, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta

2016
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
    Scientific reports, 2016, 06-23, Volume: 6

    Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Urinary Bladder Neoplasms

2016
Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells.
    Cellular oncology (Dordrecht), 2019, Volume: 42, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Basic Helix-Loop-Helix Transcription Factors; Cell Communication; Cell Line, Tumor; Cell Polarity; Chemokines, CC; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Macrophage Inflammatory Proteins; Macrophages; Metformin; Middle Aged; NF-kappa B; Receptors, CCR1; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome; Tumor Hypoxia

2019
Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.
    International journal of molecular sciences, 2020, Aug-12, Volume: 21, Issue:16

    Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Metformin; Neoplastic Stem Cells; Triple Negative Breast Neoplasms; Tumor Hypoxia; Up-Regulation

2020
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer.
    Scientific reports, 2020, 09-11, Volume: 10, Issue:1

    Topics: Afatinib; Aged; Aged, 80 and over; Antacids; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Male; Metformin; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Steroids; Treatment Failure

2020
Does metformin improve the efficacy of standard epidermal growth factor receptor-tyrosine kinase inhibitor treatment for patients with advanced non-small-cell lung cancer?
    Interactive cardiovascular and thoracic surgery, 2021, 01-01, Volume: 32, Issue:1

    Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Male; Metformin; Middle Aged; Mutation; Protein Kinase Inhibitors

2021
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
    International journal of molecular sciences, 2022, Sep-08, Volume: 23, Issue:18

    Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Metformin; Mouth Neoplasms; NF-kappa B; Squamous Cell Carcinoma of Head and Neck; Systems Biology

2022